American Society of Addiction Medicine
American Society of Addiction Medicine
Lead: Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
Lead: Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
Lead: Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
Tuesday 13th June 2023
Ketamine vs. ECT: Discover how ketamine matches ECT for treatment-resistant depression but with fewer memory problems in this insightful episode.
7 minutes
Informative
Empowering
Thought-provoking
Transformative
Hopeful
About this podcast
Author:
American Society of Addiction Medicine
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Family Recovery from Addiction
Nutritional Pathways to Recovery
Navigating Intimate Relationships
Links:
Visit site
Episodes:
140 (View all)
Do you want to link to this podcast?
Get the buttons here!Ketamine vs. ECT: A New Hope for Treatment-Resistant Depression
Episode Overview
- Comparison of ketamine and ECT for major depression
- Impact of state policies on buprenorphine treatment
- Psychological factors in psilocybin-assisted therapy for alcohol use disorder
- Experiences of clients in take-home injectable opioid agonist treatment program
- Urgency for proper screening and management of opioid use disorder
Ketamine was found to be non-inferior to ECT for treatment response as reported by decrease in depressive symptoms.
Imagine battling depression with every tool available, yet finding no relief. This episode of 'Addiction Medicine Unpacked' dives into a groundbreaking study comparing ketamine and electroconvulsive therapy (ECT) for those with treatment-resistant major depression. Hosted by Claire Rasmussen, the episode explores a noninferiority trial involving 403 patients, revealing that ketamine is just as effective as ECT in reducing depressive symptoms. However, ECT comes with a greater decline in memory performance, adding a layer of complexity to treatment choices.
The episode also touches on the exclusion of patients with psychotic features, where ketamine falls short compared to ECT. But that's not all – you'll also hear about the impact of state policies on buprenorphine treatment, the psychological nuances in psilocybin-assisted therapy for alcohol use disorder, and the firsthand experiences of clients in North America's first take-home injectable opioid agonist treatment program.
Wrapping up with urgent discussions on opioid use disorder screening and policy recommendations for alcohol misuse and gun violence, this episode offers a comprehensive look at the evolving landscape of addiction medicine. Whether you're a healthcare professional or someone affected by addiction, this episode is packed with valuable insights.